Katy has more than 15 years of scientific and managerial leadership and three years of program and alliance management across biotech and pharma industries. Her experience covers small molecules, large molecules, and cell and gene therapy within early-stage drug development across different therapeutic areas including inflammation, immunology, immune-oncology, infectious diseases, rare diseases, and musculoskeletal. For clients she leads cross-functional teams in strategy and execution of development programs. Katy partners with Halloran’s Regulatory colleagues to guide clients through early key milestone development activities such as generating integrated development plans and initial interactions with the FDA (INTERACT and Pre-IND Meetings). She also provides technical insights to clients in assay development, translational research and development and clinical biomarker strategies.

Katy started her career at Wyeth/Pfizer in Drug Discovery where she managed an enzymology and cell-based assay group and was the project lead for the first Wyeth Disease Modifying Osteoarthritis Drug (DMOAD) to enter the clinic. Katy has expertise in building cross-team collaborative relationships with multiple functional areas and has enjoyed roles both in R&D as well as program and alliance management. She has led strategic global alliances across multiple therapeutic areas and modalities resulting in milestone payments and 16 positive licensing decisions.
Prior to Halloran Katy worked at X-Chem Pharmaceuticals where she was the biology lead for two early-stage projects in rare disease and inflammation and established and implemented cell-based assays to support the development of these assets.

Education:
Arthritis Foundation Post-doctoral Fellow (Cornell University and Cleveland Clinic Foundation)
University of California, Santa Cruz, CA, PhD, Biophysical Chemistry
Indiana University Bloomington, IN, BSc, Biochemistry